{
    "xml": "<topic id=\"PHP8391\" outputclass=\"drug\" rev=\"1.17\" type=\"drug\" namespace=\"/drugs/rabies-vaccine\" basename=\"rabies-vaccine\" title=\"RABIES VACCINE\">\n<title>RABIES VACCINE</title>\n<body>\r\n<p outputclass=\"interactionsLinks\"> List of individual interactants: <xref format=\"dita\" href=\"#bnf_int_1254\" namespace=\"/interactions/list-of-drug-interactions/vaccines/rabies-vaccine\">Rabies Vaccine</xref>\n</p>\n<data name=\"vtmid\">333606008</data>\n<data name=\"classifications\">\n<data name=\"classification\">\n<data name=\"drugClassification\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClassification\" href=\"#_581448509\" title=\"Vaccines\">Vaccines</xref>\n</data>\n<data name=\"inheritsFromClass\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClass\" href=\"#PHP34568\" title=\"VACCINES\" namespace=\"/drug-classes/vaccines\">VACCINES</xref>\n</data>\n</data>\n</data>\n<data name=\"primaryDomainOfEffect\">\n<data name=\"domainOfEffect\">  </data>\n</data>\r\n</body>\n<topic id=\"PHP49314\" outputclass=\"indicationsAndDose\" rev=\"1.53\" parent=\"/drugs/rabies-vaccine\">\n<title>Indications and dose</title>\n<body>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Pre-exposure prophylaxis</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By intramuscular injection</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup child\">\n<p>Child</p>\n<p>1&#8239;mL every 1&#8239;week for 2 doses (on days 0 and 7), followed by 1&#8239;mL after 21&#8239;days for 1 dose (on day 28), to be administered in deltoid region or anterolateral thigh in infants, for those at continuous risk, measure plasma-concentration of antirabies antibodies every 6 months and give a booster dose if the titre is less than 0.5&#8239;units/mL, final dose may be given from day 21, if insufficient time before travel.</p>\n</li>\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>1&#8239;mL every 1&#8239;week for 2 doses (on days 0 and 7), followed by 1&#8239;mL after 21&#8239;days for 1 dose (on day 28), to be administered in deltoid region, for those at continuous risk, measure plasma-concentration of antirabies antibodies every 6 months and give a booster dose if the titre is less than 0.5&#8239;units/mL, final dose may be given from day 21, if insufficient time before travel.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Pre-exposure prophylaxis booster dose (for patients at frequent risk of exposure)</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By intramuscular injection</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup child\">\n<p>Child</p>\n<p>1&#8239;mL after 1&#8239;year for 1 dose, then 1&#8239;mL every 3&#8211;5&#8239;years for 1 dose, to be administered in deltoid region or anterolateral thigh in infants, the frequency of booster doses may alternatively be determined according to plasma-concentration of antirabies antibodies.</p>\n</li>\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>1&#8239;mL after 1&#8239;year for 1 dose, then 1&#8239;mL every 3&#8211;5&#8239;years for 1 dose, to be administered in deltoid region, the frequency of booster doses may alternatively be determined according to plasma-concentration of antirabies antibodies.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Pre-exposure prophylaxis booster dose (for patients at infrequent risk of exposure)</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By intramuscular injection</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup child\">\n<p>Child</p>\n<p>1&#8239;mL after 10&#8239;years for 1 dose, to be administered in deltoid region or anterolateral thigh in infants.</p>\n</li>\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>1&#8239;mL after 10&#8239;years for 1 dose, to be administered in deltoid region.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Post-exposure prophylaxis of fully immunised individuals (who have previously received pre-exposure or post-exposure prophylaxis with cell-derived rabies vaccine)</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By intramuscular injection</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup child\">\n<p>Child (administered on expert advice)</p>\n<p>1&#8239;mL for 1 dose, followed by 1&#8239;mL after 3&#8211;7&#8239;days for 1 dose, to be administered in deltoid region or anterolateral thigh in infants, rabies immunoglobulin is not necessary.</p>\n</li>\n<li outputclass=\"patientGroup adult\">\n<p>Adult (administered on expert advice)</p>\n<p>1&#8239;mL for 1 dose, followed by 1&#8239;mL after 3&#8211;7&#8239;days for 1 dose, to be administered in deltoid region, rabies immunoglobulin is not necessary.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Post-exposure treatment for unimmunised individuals (or those whose prophylaxis is possibly incomplete)</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By intramuscular injection</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup child\">\n<p>Child (administered on expert advice)</p>\n<p>1&#8239;mL 5 times a month for 1 month, doses should be given on days 0, 3, 7, 14, and the fifth dose is given between day 28&#8211;30, to be administered in deltoid region or anterolateral thigh in infants, depending on the level of risk (determined by factors such as the nature of the bite and the country where it was sustained), rabies immunoglobulin is given to unimmunised individuals on day 0 or within 7 days of starting the course of rabies vaccine, the immunisation course can be discontinued if it is proved that the individual was not at risk.</p>\n</li>\n<li outputclass=\"patientGroup adult\">\n<p>Adult (administered on expert advice)</p>\n<p>1&#8239;mL 5 times a month for 1 month, doses should be given on days 0, 3, 7, 14, and the fifth dose is given between day 28&#8211;30, to be administered in deltoid region, depending on the level of risk (determined by factors such as the nature of the bite and the country where it was sustained), rabies immunoglobulin is given to unimmunised individuals on day 0 or within 7 days of starting the course of rabies vaccine, the immunisation course can be discontinued if it is proved that the individual was not at risk.</p>\n</li>\n</ul>\n</section>\n</body>\n</topic>\n<topic id=\"PHP49260\" outputclass=\"sideEffects\" rev=\"1.11\" parent=\"/drugs/rabies-vaccine\">\n<title>Side-effects</title>\n<body>\n<section outputclass=\"generalSideEffects\">\n<sectiondiv outputclass=\"frequencies\">\n<sectiondiv outputclass=\"notKnown\">\n<p outputclass=\"title\">Frequency not known</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Paresis</ph>\n</p>\n</sectiondiv>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP49298\" outputclass=\"pregnancy\" parent=\"/drugs/rabies-vaccine\">\n<title>Pregnancy</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Because of the potential consequences of untreated rabies exposure and because rabies vaccination has not been associated with fetal abnormalities, pregnancy is not considered a contra-indication to post-exposure prophylaxis. Immunisation against rabies is indicated during pregnancy if there is substantial risk of exposure to rabies and rapid access to post-exposure prophylaxis is likely to be limited.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP8391-medicinalForms\" outputclass=\"medicinalForms\" parent=\"/drugs/rabies-vaccine\">\n<title>Medicinal forms</title>\n<body>\n<section outputclass=\"licensingVariationStatement\">\n<p>There can be variation in the licensing of different medicines containing the same drug.</p>\n</section>\n</body>\n</topic>\n<parents>\n<xref format=\"dita\" scope=\"local\" type=\"drugs\" href=\"#drugs\" title=\"Drugs\" namespace=\"/drugs\">Drugs</xref>\n</parents>\n<children>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP74691\" title=\"Powder and solvent for solution for injection\" namespace=\"/drugs/rabies-vaccine/powder-and-solvent-for-solution-for-injection\">Powder and solvent for solution for injection</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP74684\" title=\"Powder and solvent for suspension for injection\" namespace=\"/drugs/rabies-vaccine/powder-and-solvent-for-suspension-for-injection\">Powder and solvent for suspension for injection</xref>\n</children>\n<backlinks>\n<xref format=\"dita\" scope=\"local\" type=\"drugClassifications\" href=\"#PHP106980\" namespace=\"/drug-classifications\" title=\"Drug classifications\" count=\"1\" rel=\"backlink\">Drug classifications</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78196\" namespace=\"/treatment-summaries/immunoglobulins\" title=\"Immunoglobulins\" count=\"3\" rel=\"backlink\">Immunoglobulins</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78335\" namespace=\"/treatment-summaries/vaccines\" title=\"Vaccines\" count=\"5\" rel=\"backlink\">Vaccines</xref>\n</backlinks>\n<links>\n<xref format=\"dita\" scope=\"local\" type=\"interaction\" href=\"#bnf_int_1254\" namespace=\"/interactions/list-of-drug-interactions/vaccines/rabies-vaccine\" title=\"Rabies Vaccine\" count=\"1\" rel=\"link\">Rabies Vaccine</xref>\n<xref format=\"dita\" scope=\"local\" type=\"drugClass\" href=\"#PHP34568\" namespace=\"/drug-classes/vaccines\" title=\"VACCINES\" count=\"1\" rel=\"link\">VACCINES</xref>\n<xref format=\"dita\" scope=\"local\" type=\"#drugs\" href=\"#drugs\" namespace=\"/drugs\" title=\"Drugs\" count=\"1\" rel=\"link\">Drugs</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP74691\" namespace=\"/drugs/rabies-vaccine/powder-and-solvent-for-solution-for-injection\" title=\"Powder and solvent for solution for injection\" count=\"1\" rel=\"link\">Powder and solvent for solution for injection</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP74684\" namespace=\"/drugs/rabies-vaccine/powder-and-solvent-for-suspension-for-injection\" title=\"Powder and solvent for suspension for injection\" count=\"1\" rel=\"link\">Powder and solvent for suspension for injection</xref>\n</links>\n</topic>",
    "id": "PHP8391",
    "outputclass": "drug",
    "rev": "1.17",
    "type": "drug",
    "namespace": "/drugs/rabies-vaccine",
    "basename": "rabies-vaccine",
    "title": "RABIES VACCINE",
    "interactants": [
        {
            "id": "bnf_int_1254",
            "label": "Rabies Vaccine"
        }
    ],
    "vtmid": "333606008",
    "drugClassification": [
        "Vaccines"
    ],
    "inheritsFromClass": [
        "VACCINES"
    ],
    "primaryDomainOfEffect": {
        "": {
            "domain": "",
            "therapeuticUses": {}
        }
    },
    "indicationsAndDoses": {
        "indicationAndDoseGroups": [
            {
                "indications": [
                    {
                        "textContent": "Pre-exposure prophylaxis",
                        "html": "Pre-exposure prophylaxis"
                    }
                ],
                "specificity": {
                    "routes": [
                        "intramuscular injection"
                    ],
                    "textContent": "By intramuscular injection",
                    "html": "By intramuscular injection"
                },
                "child": [
                    {
                        "textContent": "1 mL every 1 week for 2 doses (on days 0 and 7), followed by 1 mL after 21 days for 1 dose (on day 28), to be administered in deltoid region or anterolateral thigh in infants, for those at continuous risk, measure plasma-concentration of antirabies antibodies every 6 months and give a booster dose if the titre is less than 0.5 units/mL, final dose may be given from day 21, if insufficient time before travel.",
                        "html": "<p>1&#8239;mL every 1&#8239;week for 2 doses (on days 0 and 7), followed by 1&#8239;mL after 21&#8239;days for 1 dose (on day 28), to be administered in deltoid region or anterolateral thigh in infants, for those at continuous risk, measure plasma-concentration of antirabies antibodies every 6 months and give a booster dose if the titre is less than 0.5&#8239;units/mL, final dose may be given from day 21, if insufficient time before travel.</p>"
                    }
                ],
                "adult": [
                    {
                        "textContent": "1 mL every 1 week for 2 doses (on days 0 and 7), followed by 1 mL after 21 days for 1 dose (on day 28), to be administered in deltoid region, for those at continuous risk, measure plasma-concentration of antirabies antibodies every 6 months and give a booster dose if the titre is less than 0.5 units/mL, final dose may be given from day 21, if insufficient time before travel.",
                        "html": "<p>1&#8239;mL every 1&#8239;week for 2 doses (on days 0 and 7), followed by 1&#8239;mL after 21&#8239;days for 1 dose (on day 28), to be administered in deltoid region, for those at continuous risk, measure plasma-concentration of antirabies antibodies every 6 months and give a booster dose if the titre is less than 0.5&#8239;units/mL, final dose may be given from day 21, if insufficient time before travel.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Pre-exposure prophylaxis booster dose (for patients at frequent risk of exposure)",
                        "html": "Pre-exposure prophylaxis booster dose (for patients at frequent risk of exposure)"
                    }
                ],
                "specificity": {
                    "routes": [
                        "intramuscular injection"
                    ],
                    "textContent": "By intramuscular injection",
                    "html": "By intramuscular injection"
                },
                "child": [
                    {
                        "textContent": "1 mL after 1 year for 1 dose, then 1 mL every 3&#8211;5 years for 1 dose, to be administered in deltoid region or anterolateral thigh in infants, the frequency of booster doses may alternatively be determined according to plasma-concentration of antirabies antibodies.",
                        "html": "<p>1&#8239;mL after 1&#8239;year for 1 dose, then 1&#8239;mL every 3&#8211;5&#8239;years for 1 dose, to be administered in deltoid region or anterolateral thigh in infants, the frequency of booster doses may alternatively be determined according to plasma-concentration of antirabies antibodies.</p>"
                    }
                ],
                "adult": [
                    {
                        "textContent": "1 mL after 1 year for 1 dose, then 1 mL every 3&#8211;5 years for 1 dose, to be administered in deltoid region, the frequency of booster doses may alternatively be determined according to plasma-concentration of antirabies antibodies.",
                        "html": "<p>1&#8239;mL after 1&#8239;year for 1 dose, then 1&#8239;mL every 3&#8211;5&#8239;years for 1 dose, to be administered in deltoid region, the frequency of booster doses may alternatively be determined according to plasma-concentration of antirabies antibodies.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Pre-exposure prophylaxis booster dose (for patients at infrequent risk of exposure)",
                        "html": "Pre-exposure prophylaxis booster dose (for patients at infrequent risk of exposure)"
                    }
                ],
                "specificity": {
                    "routes": [
                        "intramuscular injection"
                    ],
                    "textContent": "By intramuscular injection",
                    "html": "By intramuscular injection"
                },
                "child": [
                    {
                        "textContent": "1 mL after 10 years for 1 dose, to be administered in deltoid region or anterolateral thigh in infants.",
                        "html": "<p>1&#8239;mL after 10&#8239;years for 1 dose, to be administered in deltoid region or anterolateral thigh in infants.</p>"
                    }
                ],
                "adult": [
                    {
                        "textContent": "1 mL after 10 years for 1 dose, to be administered in deltoid region.",
                        "html": "<p>1&#8239;mL after 10&#8239;years for 1 dose, to be administered in deltoid region.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Post-exposure prophylaxis of fully immunised individuals (who have previously received pre-exposure or post-exposure prophylaxis with cell-derived rabies vaccine)",
                        "html": "Post-exposure prophylaxis of fully immunised individuals (who have previously received pre-exposure or post-exposure prophylaxis with cell-derived rabies vaccine)"
                    }
                ],
                "specificity": {
                    "routes": [
                        "intramuscular injection"
                    ],
                    "textContent": "By intramuscular injection",
                    "html": "By intramuscular injection"
                },
                "child": [
                    {
                        "textContent": "1 mL for 1 dose, followed by 1 mL after 3&#8211;7 days for 1 dose, to be administered in deltoid region or anterolateral thigh in infants, rabies immunoglobulin is not necessary.",
                        "html": "<p>1&#8239;mL for 1 dose, followed by 1&#8239;mL after 3&#8211;7&#8239;days for 1 dose, to be administered in deltoid region or anterolateral thigh in infants, rabies immunoglobulin is not necessary.</p>",
                        "ageGroup": "(administered on expert advice)"
                    }
                ],
                "adult": [
                    {
                        "textContent": "1 mL for 1 dose, followed by 1 mL after 3&#8211;7 days for 1 dose, to be administered in deltoid region, rabies immunoglobulin is not necessary.",
                        "html": "<p>1&#8239;mL for 1 dose, followed by 1&#8239;mL after 3&#8211;7&#8239;days for 1 dose, to be administered in deltoid region, rabies immunoglobulin is not necessary.</p>",
                        "ageGroup": "(administered on expert advice)"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Post-exposure treatment for unimmunised individuals (or those whose prophylaxis is possibly incomplete)",
                        "html": "Post-exposure treatment for unimmunised individuals (or those whose prophylaxis is possibly incomplete)"
                    }
                ],
                "specificity": {
                    "routes": [
                        "intramuscular injection"
                    ],
                    "textContent": "By intramuscular injection",
                    "html": "By intramuscular injection"
                },
                "child": [
                    {
                        "textContent": "1 mL 5 times a month for 1 month, doses should be given on days 0, 3, 7, 14, and the fifth dose is given between day 28&#8211;30, to be administered in deltoid region or anterolateral thigh in infants, depending on the level of risk (determined by factors such as the nature of the bite and the country where it was sustained), rabies immunoglobulin is given to unimmunised individuals on day 0 or within 7 days of starting the course of rabies vaccine, the immunisation course can be discontinued if it is proved that the individual was not at risk.",
                        "html": "<p>1&#8239;mL 5 times a month for 1 month, doses should be given on days 0, 3, 7, 14, and the fifth dose is given between day 28&#8211;30, to be administered in deltoid region or anterolateral thigh in infants, depending on the level of risk (determined by factors such as the nature of the bite and the country where it was sustained), rabies immunoglobulin is given to unimmunised individuals on day 0 or within 7 days of starting the course of rabies vaccine, the immunisation course can be discontinued if it is proved that the individual was not at risk.</p>",
                        "ageGroup": "(administered on expert advice)"
                    }
                ],
                "adult": [
                    {
                        "textContent": "1 mL 5 times a month for 1 month, doses should be given on days 0, 3, 7, 14, and the fifth dose is given between day 28&#8211;30, to be administered in deltoid region, depending on the level of risk (determined by factors such as the nature of the bite and the country where it was sustained), rabies immunoglobulin is given to unimmunised individuals on day 0 or within 7 days of starting the course of rabies vaccine, the immunisation course can be discontinued if it is proved that the individual was not at risk.",
                        "html": "<p>1&#8239;mL 5 times a month for 1 month, doses should be given on days 0, 3, 7, 14, and the fifth dose is given between day 28&#8211;30, to be administered in deltoid region, depending on the level of risk (determined by factors such as the nature of the bite and the country where it was sustained), rabies immunoglobulin is given to unimmunised individuals on day 0 or within 7 days of starting the course of rabies vaccine, the immunisation course can be discontinued if it is proved that the individual was not at risk.</p>",
                        "ageGroup": "(administered on expert advice)"
                    }
                ]
            }
        ]
    },
    "sideEffects": {
        "general": {
            "frequencies": {
                "notKnown": [
                    {
                        "type": "notKnown",
                        "textContent": "Paresis",
                        "html": "Paresis",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    }
                ]
            }
        }
    },
    "pregnancy": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Because of the potential consequences of untreated rabies exposure and because rabies vaccination has not been associated with fetal abnormalities, pregnancy is not considered a contra-indication to post-exposure prophylaxis. Immunisation against rabies is indicated during pregnancy if there is substantial risk of exposure to rabies and rapid access to post-exposure prophylaxis is likely to be limited.",
                "html": "<p>Because of the potential consequences of untreated rabies exposure and because rabies vaccination has not been associated with fetal abnormalities, pregnancy is not considered a contra-indication to post-exposure prophylaxis. Immunisation against rabies is indicated during pregnancy if there is substantial risk of exposure to rabies and rapid access to post-exposure prophylaxis is likely to be limited.</p>"
            }
        ]
    },
    "medicinalForms": {
        "licensingVariationStatement": [
            {
                "type": "licensingVariationStatement",
                "textContent": "There can be variation in the licensing of different medicines containing the same drug.",
                "html": "<p>There can be variation in the licensing of different medicines containing the same drug.</p>"
            }
        ]
    },
    "children": {
        "medicinalForm": [
            {
                "id": "PHP74691",
                "label": "Powder and solvent for solution for injection",
                "type": "medicinalForm"
            },
            {
                "id": "PHP74684",
                "label": "Powder and solvent for suspension for injection",
                "type": "medicinalForm"
            }
        ]
    },
    "backlinks": {
        "drugClassifications": [
            {
                "id": "PHP106980",
                "label": "Drug classifications",
                "type": "drugClassifications"
            }
        ],
        "treatmentSummary": [
            {
                "id": "PHP78196",
                "label": "Immunoglobulins",
                "type": "treatmentSummary"
            },
            {
                "id": "PHP78335",
                "label": "Vaccines",
                "type": "treatmentSummary"
            }
        ]
    },
    "links": {
        "interaction": [
            {
                "id": "bnf_int_1254",
                "label": "Rabies Vaccine",
                "type": "interaction"
            }
        ],
        "drugClass": [
            {
                "id": "PHP34568",
                "label": "VACCINES",
                "type": "drugClass"
            }
        ],
        "#drugs": [
            {
                "id": "drugs",
                "label": "Drugs",
                "type": "#drugs"
            }
        ],
        "medicinalForm": [
            {
                "id": "PHP74691",
                "label": "Powder and solvent for solution for injection",
                "type": "medicinalForm"
            },
            {
                "id": "PHP74684",
                "label": "Powder and solvent for suspension for injection",
                "type": "medicinalForm"
            }
        ]
    }
}